Austar LifesciencesAULSF 49 Current Ratio is 1.36 as of Dec. 2025, which is 4% below its 10-year median of 1.41. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.10. The stock has 6 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 80.33% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Austar Lifesciences's current ratio for the quarter that ended in Dec. 2025 was 1.36.
Austar Lifesciences has a current ratio of 1.36. It generally indicates good short-term financial strength.
The historical rank and industry rank for Austar Lifesciences's Current Ratio or its related term are showing as below:
AULSF'
s Current Ratio Range Over the Past 10 Years
Min: 1.31 Med: 1.41 Max: 2.25
Current: 1.36
During the past 13 years, Austar Lifesciences's highest Current Ratio was 2.25. The lowest was 1.31. And the median was 1.41.
AULSF's Current Ratio is ranked worse than 80.33% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.475
vs AULSF: 1.36
Austar Lifesciences (OTCPK:AULSF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Austar Lifesciences Current Ratio Related Terms
Austar Lifesciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a Current Ratio of 1.36 as of Dec. 2025. This is near median its historical median of 1.41. Over the past decade, Austar Lifesciences' Current Ratio has ranged from 1.31 to 2.25. According to the industry distribution chart, Austar Lifesciences ranks #686 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 80.3%.
Is Austar Lifesciences' Current Ratio too high?
Austar Lifesciences' current Current Ratio of 1.36 is near median its 10-year median of 1.41. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 2.25. The Medical Devices & Instruments industry median Current Ratio is 2.48. Austar Lifesciences' value of 1.36 is 45.1% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #686 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #686 out of 854 companies for Current Ratio. This places Austar Lifesciences in the lower half of its industry. The industry median Current Ratio is 2.48. Austar Lifesciences' value of 1.36 is 45.1% below this benchmark. Historically, Austar Lifesciences' own Current Ratio has ranged from 1.31 to 2.25 over the past decade. While the company's 10-year median is 1.41 vs. the industry median of 2.48, Austar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.48, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current Current Ratio of 1.36 is 45.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current Current Ratio is 1.36, which is near median its own 10-year median of 1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current Current Ratio of 1.36. The stock's GF Value™ is $0.10, compared to a current price of $0.02 — trading 80% below its estimated fair value. The current Current Ratio is 1.36, which is near median its 10-year median of 1.41 and 45.1% below the Medical Devices & Instruments industry median of 2.48. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Current Ratio is 1.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 80% below its estimated GF Value™ of $0.10.
Key valuation signals for AULSF:
Current Ratio: 1.36 (near median its 10-year median of 1.41)
GF Value™: $0.10 vs. price of $0.02 (80% below fair value)
Industry Position: 45.1% below the Medical Devices & Instruments median (#686 of 854)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
